The present invention relates to targeted prevention of vertical transmission of infection between mother and foetus. More particularly, the invention relates to methods of preventing neonatal Fc receptor (FcRn)-mediated transmission of virus, preferably flavivirus, more preferably Zika virus (ZIKV), from a mother immune to a cross-reactive virus e.g. Dengue virus (DENY) to her foetus, and to reagents that block or inhibit said FcRN-mediated transmission of virus.

The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody.

The present invention relates to compositions and methods associated with antibody-bacterial effector translocase protein conjugates. Some aspects of the present invention relate to preventing or treating diseases using the antibody-protective antigen conjugates. Further aspects of the present invention relate to methods of chemically conjugating and synthesizing the antibody-bacterial effector translocase protein conjugates.

A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.

Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.

The present disclosure is directed to the use of an IL33-axis binding antagonist for the treatment and prevention of acute respiratory distress syndrome (ARDS) and/or symptoms thereof.

Provided are methods for treating paroxysmal nocturnal hemoglobinuria in a subject who previously exhibited an inadequate response to an anti-C5 antibody therapy, by administering to the subject a therapeutically effective amount of an inhibitor of the alternative pathway of complement (e.g., one which inhibits a target upstream to complement 5 (C5), such as Factor D or complement 3 (C3)). Also provided herein are methods for treating PNH in a human subject, comprising administering to the subject a complement factor D inhibitor alone or in combination with an anti-C5 antibody, or antigen binding fragment thereof. In some embodiments, the patient previously exhibited an inadequate response to an anti-C5 antibody therapy.

The present disclosure relates to a method of treating a HER2 positive cancer in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a combination therapy comprising tucatinib, trastuzumab, and an oxaliplatin-based chemotherapy.

The present invention provides an expression vector, host cells, methods and kits for the treatment or prevention of a flavivirus infection in a subject.

The present disclosure provides immunogenic materials and methods useful for reducing the risk of fungal infections, particularly valley fever. The disclosure also provides assays for identifying compounds useful to treat valley fever, as well as methods for ameliorating the symptoms of valley fever.